Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2023 Earnings Conference Call March 28, 2024 4:30 PM ET

Company Participants

Sabrina Martucci Johnson - President and CEO
MarDee Haring-Layton - Chief Accounting Officer

Conference Call Participants

Douglas Tsao - H.C. Wainright
Will Hidell - Brookline Capital Markets

Operator

Welcome to the conference call hosted by Daré Bioscience to review the company’s Fourth Quarter Financial Results and to provide a General Business Update. This call is being recorded. My name is Lisa, and I will be your operator today. With us today from Daré are Sabrina Martucci Johnson, President and Chief Executive Officer; and MarDee Haring-Layton, Chief Accounting Officer.

Ms. Johnson, please proceed.

Sabrina Martucci Johnson

Thank you. Good afternoon. And welcome to the Daré Bioscience financial results and business update call for the year ended December 31, 2023. Today, we’ll review our financial results for 2023 and discuss developments and expectations for our pipeline and portfolio.

Before we begin, I’d like to remind you that today’s discussion will include forward-looking statements within the meaning of federal securities laws, which are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995.

Any statements made during this call that are not statements of historical facts should be considered forward-looking statements. Actual results or events could differ materially from those anticipated or implied by these statements due to known and unknown risks and uncertainties.

You should not place undue reliance on forward-looking statements. Forward-looking statements are qualified in their entirety by the cautionary statements in the company’s SEC filings, including our Form 10-K for the year ended December 31, 2023, which was filed today.

I would also like to point out that the content of this call includes time-sensitive information that is current only as of today, March 28, 2024. Daré undertakes no obligation to update any forward-looking statements to reflect new information or developments after this call, except as required by law.

As you know, women’s health is our sole focus at Daré. Women’s health products make up 27% of total blockbuster products, while contributing to 35% of total blockbuster sales and there continue to be many unmet needs in the market.

To our knowledge, Daré is the only publicly-traded company focused solely on women’s health pharmaceutical product development broadly, and we remain committed to advancing through clinical development, regulatory review and ultimately to market disruptive products for women.